Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.90 |
| ▸ | RAF1 | P04049 | 7/20 | 0.90 |
| ▸ | KDR | P35968 | 5/20 | 0.90 |
| ▸ | LCK | P06239 | 3/20 | 0.90 |
| ▸ | FYN | P06241 | 3/20 | 0.90 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.90 |
| ▸ | KIT | P10721 | 3/20 | 0.90 |
| ▸ | FLT1 | P17948 | 3/20 | 0.90 |
| ▸ | FLT4 | P35916 | 3/20 | 0.90 |
| ▸ | STK25 | O00506 | 1/20 | 0.90 |
| ▸ | CIT | O14578 | 1/20 | 0.90 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.90 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.90 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.90 |
| ▸ | PAK3 | O75914 | 1/20 | 0.90 |
| ▸ | STK10 | O94804 | 1/20 | 0.90 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.90 |
| ▸ | ABL1 | P00519 | 1/20 | 0.90 |
| ▸ | CSF1R | P07333 | 1/20 | 0.90 |
| ▸ | YES1 | P07947 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raf-265 SCHEMBL29355586 | 0.95 | BRAF (1.00) | BRAFRAF1KDRLCKFYN | |
| Raf-265 SCHEMBL686452 | 0.95 | BRAF (1.00) | BRAFRAF1KDRLCKFYN | |
| Raf-265 SCHEMBL1562237 | 0.95 | BRAF (1.00) | BRAFRAF1KDRLCKFYN | |
| Raf-265 SCHEMBL29368571 | 0.95 | BRAF (1.00) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL19661215 | 0.93 | BRAF (0.91) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL1435408 | 0.92 | BRAF (1.00) | BRAFRAF1KDRLCKFYN | |
| Raf-265 SCHEMBL1562780 | 0.90 | BRAF (0.91) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL13167356 | 0.90 | BRAF (0.74) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL13167316 | 0.90 | BRAF (0.84) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL12811763 | 0.89 | BRAF (0.83) | BRAFRAF1KDRLCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180214449-A1 | CANCER THERAPY USING JAK INHIBITOR IN COMBINATION WITH MAPK INHIBITORS | UBRX, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20160101106-A1 | METHODS FOR TREATING HCV INFECTION | INHIBIKASE THERAPEUTICS, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-8501785-B2 | Salts of benzimidazolyl pyridyl ethers and formulations thereof | NOVARTIS AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8501785-B2 | Salts of benzimidazolyl pyridyl ethers and formulations thereof | NOVARTIS AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8455662-B2 | Formulations for benzimidazolyl pyridyl ethers | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455662-B2 | Formulations for benzimidazolyl pyridyl ethers | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8202998-B2 | Salts of benzimidazolyl pyridyl ethers and formulations thereof | NOVARTIS AG (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100168060-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100040677-A1 | FORMULATIONS FOR BENZIMIDAZOLYL PYRIDYL ETHERS | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101106-A1 | METHODS FOR TREATING HCV INFECTION | HAVCR2, RAF1, BRAF | BRAF 3/4885RAF1 2/4885KDR 3607/4885 |
| US-20100040677-A1 | FORMULATIONS FOR BENZIMIDAZOLYL PYRIDYL ETHERS | PIR, TP53RK, ALK | BRAF 174/4885RAF1 636/4885KDR 2198/4885 |
| US-20100168060-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | PIR, BRD8, PHOSPHO1 | BRAF 542/4885RAF1 874/4885KDR 2799/4885 |
| US-20180214449-A1 | CANCER THERAPY USING JAK INHIBITOR IN COMBINATION WITH MAPK INHIBITORS | JAK2, JAK1, JAK3 | BRAF 42/4885RAF1 98/4885KDR 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.